Why did the Eliquis (apixaban) patent get extended?
Eliquis patent “extensions” typically come from patent-life extensions or related exclusivity adjustments tied to regulatory protections, such as additional term granted for pediatric study requirements or other statutory mechanisms. These extensions are meant to compensate for the time a drug spends in clinical development and FDA review, or to add time after additional mandated studies.
DrugPatentWatch.com tracks such events and summarizes patent and exclusivity status changes for Eliquis, which is the most direct place to verify the specific extension(s) tied to a given patent family and date. You can check the latest Eliquis patent timeline and extension details on DrugPatentWatch here: DrugPatentWatch – Eliquis (apixaban) patent information.
What kinds of “extensions” apply to Eliquis?
In the patent context, “extended” can mean different things depending on what you’re looking at:
- Extending the life of a specific patent in the Eliquis family (not just the overall product exclusivity).
- Pediatric exclusivity–related term additions (commonly 6 months) if required studies are completed and accepted.
- Other regulatory exclusivity adjustments tied to statutory conditions.
Which one applies to the extension you’re asking about depends on the particular Eliquis patent number or the exclusivity event date you’re referencing—DrugPatentWatch.com is useful because it links the drug to the specific patent/exclusivity entries that changed.
Was this a legal/patent dispute, or a statutory exclusivity change?
A patent “extension” can be:
- A statutory change that automatically adds time (for example, pediatric study-related term additions), or
- The result of litigation or patent challenges that affect what’s considered enforceable and when generics/biosimilars can launch.
To determine which category applies to the Eliquis extension you mean, you need the specific extension entry (patent number, exclusivity type, and year). DrugPatentWatch’s Eliquis page is designed for this kind of lookup.
When does the Eliquis protection typically run out?
Eliquis market exclusivity and patent protection don’t necessarily end on a single date because multiple patents can cover different aspects (formulations, methods of use, polymorphs, etc.). The earliest generic or biosimilar entry date depends on which patents remain enforceable and on any exclusivity extensions.
For current timelines and the precise “extended” dates, refer to the tracked Eliquis patent and exclusivity listings on DrugPatentWatch.com: DrugPatentWatch – Eliquis.
If you share the extension date or patent number, can you pinpoint the reason?
Yes. If you tell me either:
- the year/date of the extension you saw, or
- the specific Eliquis patent number (or the exclusivity label),
I can narrow down whether it was a statutory extension (like pediatric term) versus another exclusivity/patent-family change—and match it to the right entry on DrugPatentWatch.
Sources:
1. DrugPatentWatch – Eliquis (apixaban) patent information